Business
Guardant Health to present 17 scientific abstracts highlighting contribution of its blood tests and real-world data to advances in precision oncology and cancer screening at 2023 ASCO annual meeting
New research further confirms value of interrogating epigenomic signals with Guardant Infinity™ platform to identify novel biomarker targets and predict
About this update from Guardant Health, Inc.
[{"type":"text","content":"\nNew research further confirms value of interrogating epigenomic signals with Guardant Infinity™ platform to identify novel biomarker targets and predict treatment resistance\n\n\n PALO ALTO, Calif.--(BUSINESS WIRE)--\nGuardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, announced today that the company and its research collaborators will present data from 17 studies that highlight the contribution of Guardant blood tests and real-world data to advances in precision oncology and cancer screening at the 2023 American Society for Clinical Oncology (ASCO) Annual Meeting, June 2-6 in Chicago.\n\n\nData being presented from multiple studies demonstrate the utility of Guardant Health’s portfolio of cancer tests to help healthcare professionals optimize care for patients at all stages of the disease—from detecting early-stage cancers to identifying the presence of residual disease and delivering insights that inform treatment to improve outcomes.\n\n\n“We look forward to sharing new data at ASCO that demonstrate scientific and clinical advances across the entire continuum of cancer care,” said Helmy Eltoukhy, Guardant Health chairman and co-CEO. “In particular, research demonstrating the tremendous potential of epigenomic analysis through our new Guardant Infinity platform shows how gaining deeper insights into the tumor microenvironment can help us identify new potential biomarker targets for therapy and predictive markers for treatment resistance.”\n\n\nFeatured presentations include:\n\n\n\nGuardant Health will present a session highlighting the performance of the Guardant Infinity platform in the detection of homologous recombination deficiency (HRD) status in patients with breast cancer. With HRD prediction, the platform provides a comprehensive, minimally invasive solution for PARPi and DNA damage treatment selection and longitudinal monitoring, and an exploratory platform for investigating epigenetic signals that may underpin resistance. (Abstract 556, Sunday, June 4, 8-11am, Hall A)\n\n\n\n\nGuardant Health collaborators will present a session on the ESR1 mutational landscape and the impact of co-existing resistance variants on clinical outcomes in patients with metastatic breast cancer. The study demonstrates that plasma-based genotyping can detect ESR1 mutations that qualify patients to receive FDA-appro...